JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Satoshi Yamamoto
Katsunobu Kawahara
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Yamashita, S.-i.
Right arrow Articles by Kawahara, K.
PubMed
Right arrow Articles by Yamashita, S.-i.
Right arrow Articles by Kawahara, K.
Related Collections
Right arrow Lung - cancer
Right arrow Molecular biology
Right arrow Lung - basic science

J Thorac Cardiovasc Surg 2009;138:1303-1308
© 2009 The American Association for Thoracic Surgery

General Thoracic Surgery

Expression of dual-specificity tyrosine-(Y)-phosphorylation–regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma

Shin-ichi Yamashita, MD*, Masao Chujo, MD, Keita Tokuishi, MD, Kentaro Anami, MD, Michiyo Miyawaki, MD, Satoshi Yamamoto, MD, Katsunobu Kawahara, MD

Department of Surgery II, Faculty of Medicine, Oita University, Oita, Japan

Received for publication May 1, 2009; revisions received July 16, 2009; accepted for publication August 7, 2009.

* Address for reprints: Shin-ichi Yamashita, Department of Surgery II, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu, Oita, 879-5593, Japan. (Email: yamashi1{at}med.oita-u.ac.jp).

Objectives: We investigated the possibility of DYRK2, a dual-specificity tyrosine-(Y)-phosphorylation–regulated kinase gene, to predict survival for patients with pulmonary adenocarcinoma.

Patients and Methods: One hundred forty-four patients with pulmonary adenocarcinoma underwent surgery in our institute from 2000 to 2008. We used immunohistochemical analysis and real-time reverse-transcriptase polymerase chain reaction to determine the expression of DYRK2 and compared this with the clinicopathologic factors and survival.

Results: We found no correlation between DYRK2 expression by immunohistochemical and clinicopathologic factors; however, a negative nodal status and negative lymphatic invasion were significantly associated with DYRK2 expression by reverse-transcriptase polymerase chain reaction. Five-year disease-free survival in the DYRK2-positive group (75.4%) was significantly different from that in the negative group (55.4%; P = .03) by immunohistochemical analysis. The 5-year overall survival of 89.2% in the DYRK2-positive group was better than the 66.3% survival of the DYRK2-negative group (P = .01). Quantitative real-time reverse-transcriptase polymerase chain reaction analyses showed a significant difference between positive and negative expressions for disease-free survival (P = .003) and overall survival (P = .007). In multivariate Cox regression analysis, negative DYRK2 protein and messenger RNA expression showed a worse prognostic value of survival (hazard ratio [HR] = 4.7, 95% confidence intervals [CI] = 1.5–14.5, P=.007; HR = 2.5, 95% CI = 1.1–6.1, P = .04, respectively). When we analyzed adenocarcinoma cases except for bronchioloalveolar carcinoma, we found a close correlation between DYRK2 expression by immunohistochemical analysis and nodal status (P = .03). Furthermore, disease-free survivals between positive and negative groups of DYRK2 expression by immunohistochemistry (P = .03) and reverse-transcriptase polymerase chain reaction (P = .02) without bronchioloalveolar carcinoma were significantly different. Overall survivals in both groups showed significant differences by immunohistochemistry (P = .02) but not by reverse-transcriptase polymerase chain reaction (P = .08).

Conclusions: These data showed that DYRK2 expression is associated with a favorable prognosis.

Abbreviations and Acronyms BAC = bronchioloalveolar carcinoma; CI = confidence interval; HR = hazard ratio; IHC = immunohistochemistry (immunohistochemical); mRNA = messenger RNA; PCR = polymerase chain reaction; RT-PCR = reverse-transcriptase polymerase chain reaction






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The American Association for Thoracic Surgery.